Jay R. Luly - Mar 13, 2023 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
President and CEO, Director
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Mar 13, 2023
Transactions value $
-$869,860
Form type
4
Date filed
3/14/2023, 06:26 PM
Previous filing
Feb 15, 2023
Next filing
Nov 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $391K +27.9K +3.4% $14.00 848K Mar 13, 2023 Direct
transaction ENTA Common Stock Sale -$479K -10.7K -1.26% $44.81 837K Mar 13, 2023 Direct F1, F2
transaction ENTA Common Stock Sale -$709K -15.6K -1.87% $45.31 821K Mar 13, 2023 Direct F1, F3
transaction ENTA Common Stock Sale -$72.2K -1.57K -0.19% $46.13 820K Mar 13, 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -27.9K -100% $0.00* 0 Mar 13, 2023 Common Stock 27.9K $14.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in September 2022.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.39 to $44.99, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.99, inclusive.
F4 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.54, inclusive.
F5 On March 21, 2013, the reporting person was granted an option to purchase 83,526 shares of common stock, half of which became exercisable upon the achievement of several clinical milestones during the four-year performance period after the date of grant.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4 above.